Premium
Successful immunotherapy of the highly metastatic murine ESb lymphoma with sensitized CD8 + T cells and IFN‐α/β
Author(s) -
Kaido Thomas,
Maury Chantal,
Schirrmacher Volker,
Gresser Ion
Publication year - 1994
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.2910570417
Subject(s) - spleen , immune system , cd8 , adoptive cell transfer , splenocyte , immunology , immunotherapy , alpha (finance) , lymphoma , beta (programming language) , cancer research , biology , medicine , t cell , construct validity , nursing , patient satisfaction , computer science , programming language
Abstract Daily IFN‐α/β therapy was totally ineffective in inhibiting the development of visceral metastases in DBA/2 mice injected i.v. with the ESb lymphoma regardless of the number of tumor cells injected. The finding that IFN‐α/β therapy increased the survival time of ESb‐tmmunized mice rechallenged with ESb cells suggested that cooperation between the immune system and IFN‐α/β was important. Adoptive transfer of ESb‐immune spleen cells (but not normal cells) together with IFN‐α/β treatment did inhibit the development of ESb metastases in immunocompetent DBA/2 mice. Either treatment alone was ineffective. The anti‐metastatic effect was specific for the ESb lymphoma as spleen cells from ESb‐immunized mice together with IFN‐α/β treatment did not inhibit the development of metastases in mice challenged with IFN‐α/β‐resistant 3C18 FLC. Depletion of CD8 + T cells (but not CD4 + T cells or B lymphocytes) prior to transfer eliminated the protective effect of ESb‐immune splenocytes in IFN‐α/β‐treated mice. As few as 1 × 10 6 ESb‐immune spleen cells highly enriched for CD8 + cells increased the survival time of IFN‐α/β‐treated ESb‐challenged DBA/2 mice. The combined therapy of ESb‐specific immune cells and IFN‐α/β resulted in long‐term immunity to this tumor. © 1994 Wiley‐Liss, Inc.